BioSpace News Archive

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

Iotron Medical Inc. and Canadian Isotope Innovations Corp. are pleased to announce a collaboration to produce the radioisotope copper-67 for new cancer therapies.

Cardiff Oncology, Inc. today announced that it will host a virtual KOL event for analysts, investors, and the scientific community on Wednesday, September 8, 2021.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda®), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.

The FDA removed one more hurdle to launching new products in the U.S. when it gave full approval to the Pfizer/NioNTech vaccine.

Aerami Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for imatinib for treatment of patients with pulmonary arterial hypertension (PAH).

Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two ophthalmic drugs, Emadine® and Betopic® S, in Mainland China and obtain the transfer of the corresponding manufacturing technology.

argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that it has submitted, and the European Medicines Agency has validated, the marketing authorization application for the Company’s investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis.

Remote healthcare is a telemedicine service that uses a mobile device to constantly monitor a patient’s condition and performance outside a medical facility.